News

Neurimmune announced today that NovaGo Therapeutics, a company of the Neurimmune group, closed a USD 30 million Series B financing round, co-led by Neurimmune and Pureos Bioventures, with participation from additional new and existing investors.

Neurimmune today announced that new cardiac MRI analyses assessing the regional effects of cliramitug on cardiac amyloid depletion, structure and function in participants from the Phase 1b study will be presented at ESC Congress 2026 in Munich.

Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the company access to non-dilutive funding for the development of its R&D pipeline.

Neurimmune announced today that safety and efficacy data of the long-term follow up of the NI006-101 trial of cliramitug have been published in Nature Medicine.

Neurimmune today announced its participation in the upcoming 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2026) in Copenhagen, Denmark.

Neurimmune today announced that the company joined the ACCESS-AD consortium, a new European initiative to accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management in real-world health systems.

AL-S Pharma will present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15, 2026.

AL-S Pharma today presented its Phase 2 clinical study results on AP-101 at the 36th International Symposium on ALS/MND in San Diego.

Neurimmune today announced that it has expanded on its ATTR-CM collaboration with Alexion, AstraZeneca Rare Disease by entering into a collaboration and license agreement to develop NI009 for the treatment of AL amyloidosis.